Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I wonder if we would make an agreement with the other members of the UK RTC for the production of Mologics Antigen LFT? It would make sense as with our other commitments we would have trouble meeting potential demand on our own
I cannot see an RNS pre-presentation, otherwise it loses the impact of the presentation. 4.30pm, listen to Colin et al provide a trading update to 30/9 which is a largely irrelevant trading period as Covid production only started late in that period. Then a update on progress to date on key products, with some forward guidance on production volumes, then Q&A.
Trading update RNS will either be at 16.30 or at some point pre 7.00am the following morning.
I'm hoping for some golden nuggets but <5% chance IMHO.
Tomorrow will be an updated business plan. The 6 month interim results will be secondary to the forward looking and status updates on:
Elisa test approvals and sales - I think many expect that the first batch of Senegal tests are the only sales becasue we havn't had RNS on sales or contracts. I think we will be pleasantly surprised on progress of Elisa tests. I am expecting confirmation of further approvals and sales in several locations including India. We could also get an update on the plan to increase Elisa testing capacity.
UK RTC update - not sure there is too much new to be updated here as will need to come via a formal UK RTC update. We could hear about current production, is production live and how many? He could explain that the supply agreement should effectively be treated as an order of 200k tests per week from Abingdon.
Visitect Antibody update - Early indication of sales. Current production update. WHO approval update
Timelines on Antigen Elisa and LFT - must be very close now.
Capacity plan - I am half expecting CK to announce the expansion of capacity up to 2.5m tests in the update tomorrow. I feel there will be at least one big bit of news and this could be it as CK can potentially control the timing of this. It is also interesting that the timing of this is consistent with the expected CE mark of Mologic's antigen test by end of Oct, and CKs earlier comment that expansion was directly in relation to Moonshot. As a minimum we should get an update on the existing plan to go to 1m and the status of the procurement of kit.
CD4 tests - Update on orders, confirmation of existing agreements moving forward. Any progress on US?
Food tests - update on china self test approval
Trading update can offer a bit of creative licence so it will be interesting to see how transparent it is or if it is a box ticking exercise to get out of the way before further news. I personally think there is a hell of a lot going on form the day to day operations and that this could be a good opportunity to start adding the necessary colour to show that operationally the business is moving forward quickly despite the fact that it might not come across with newsflow.
Fair point J
Wasn’t expecting much tbh. Let’s hope it’s a day without big swings.
I think 16:30 RNS.
If the SP tanks then the online update agenda @16:30 goes out the window. I don’t think that makes any sense.
Also I believe the whole point of the update being at 16:30 will be to allow people to digest the information.
Not to be confused with I expect the SP to tank.
I did think they maybe opted for after hours presentation as a result of the share price volatility in the last event .
Cavity- a trading update is being issued@ 16:30 on Wednesday along with an investor presentation. It doesn’t say an Rns @ 0700 Wednesday morning?